Diabetes, nutrition & metabolism最新文献

{"title":"Comparative in vitro uptake of zinc by erythrocytes of normal vs Type 2 diabetic individuals and the associated factors.","authors":"V V Agte,&nbsp;R V Nagmote,&nbsp;K V Tarwadi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diabetes is an oxidative stress-related disorder in which erythrocyte zinc uptake may vary as compared to healthy individuals. Since zinc is one of the important antioxidant trace metals, some functional indices of erythrocyte zinc status, ie in vitro zinc uptake, osmotic fragility and glucose uptake, were compared in Type 2 diabetic subjects (n=43) and healthy controls (n=22). The associations of these indices with plasma levels of antioxidants and micronutrients were examined. The trace metals were analyzed by atomic absorption spectrophotometer. Vitamins were estimated using spectrophotometric and spectroflourometric methods. In vitro zinc uptakes of healthy subjects were 17 to 52% higher (p<0.01) than those for diabetic subjects. The osmotic fragility for diabetic cells was 2.2 to 1.5 times higher than the healthy cells in 0.85-0.5% NaCl solutions (p<0.05). Percent hemolysis at 0.75, 0.65 and 0.55% NaCl had significant negative correlations (p<0.05) with in vitro zinc uptakes and that at 0.50% NaCl had a positive correlation with HbA1c levels (p<0.05). The in vitro zinc uptakes of erythrocytes in healthy subjects showed a strong negative correlation (p<0.01) with percent hemolysis at 0.75, 0.65 and 0.55% NaCl, a positive correlation with plasma zinc (r=0.33, p<0.05) and a strong negative correlation with plasma selenium and iron, hemoglobin and serum ceruloplasmin indicating antagonistic behavior of copper, iron and selenium with zinc uptake (p<0.01). Furthermore, erythrocyte super oxide dismutase (SOD), plasma ascorbic acid and status of riboflavin and thiamine were negatively correlated with in vitro zinc uptakes of erythrocytes in healthy subjects (p<0.01). These associations in the diabetic subjects were weaker than normal. Erythrocyte zinc uptake and osmotic fragility could be biomarkers of long-term zinc status and decrease of zinc uptake may be one of the features of diabetic patients.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"343-9"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25105316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum sialic acid and carbohydrate-deficient transferrin concentration in Type 2 diabetes mellitus with and without macrovascular complications.","authors":"L Chrostek,&nbsp;B Cylwik,&nbsp;A Poplawska,&nbsp;M Szmitkowski,&nbsp;A Koput","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"371-3"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25105320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microalbuminuria, brain vasomotor reactivity, carotid and kidney arterial flow in Type 2 diabetes mellitus.","authors":"F Gregorio,&nbsp;F Ambrosi,&nbsp;F Carle,&nbsp;M Boemi,&nbsp;M Boscaro,&nbsp;M G Ceravolo,&nbsp;L Evangelisti,&nbsp;E Bordoni,&nbsp;C Sardu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diabetic microangiopathy produces widespread small vessel impairment which particularly affects renal glomeruli functions. Microalbuminuria is the earliest marker of microangiopathic kidney disease and has also recently been recognised as a marker of macroangiopathic cardiovascular involvement. To determine correlations between daily microalbuminuria, local microangiopathic kidney damage, systemic macroangiopathic involvement and functional brain microcirculation, 70 Type 2 diabetic subjects who were diagnosed more than 5 years ago underwent carotid (to determine index of macro- and microangiopathy) and interlobar kidney artery color Doppler (to determine microangiopathic involvement), transcranial Doppler (to determine alterations in brain vasomotor reserve), and evaluation of daily albumin excretion rate. All the indices of microcirculatory involvement in the kidney, brain and small vessels downstream-from the carotid arteries were closely related (for all p<0.001) but never correlated with the macroangiopathy index. Daily microalbuminuria correlated with all the micro- (p<0.0001) and macroangiopathic (p<0.005) Doppler indices. These findings confirm that microangiopathy is the main cause of the diabetic increase in the albumin excretion rate and support the view that microalbuminuria can be considered a powerful biomarker of widespread macroangiopathy. Our results suggest microalbuminuria may also identify cerebrovascular diabetic involvement, as it predicts both macroangiopathic carotid alteration and microvascular brain impairment.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"323-30"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25277278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.","authors":"P Brunetti,&nbsp;G Pagano,&nbsp;C Turco,&nbsp;M Gori,&nbsp;G Perriello","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A double-blind, prospective, randomised, cross-over clinical trial was performed comparing a glibenclamide (G) 5.0 mg/metformin (M) 400 mg combination with a G 2.5 mg/M 400 mg formulation to evaluate whether a higher dose of glibenclamide was able to improve glycaemia in poorly controlled Type 2 diabetic patients. One hundred and ninety-eight patients with poorly controlled Type 2 diabetes mellitus were randomised to receive one of the two trial drugs for a first 3-month period, and were then assigned to the alternative combination for further 3 months. The starting dose (2 tablets/day, 30 min before breakfast and dinner) was to be up-titrated to 3 tablets/day when required. A standard dietary regimen was kept constant for the total trial duration. Fasting plasma glucose, HbA1c, C-peptide, insulin and lactate levels, haematology and blood chemistry were measured at the start/end of each cycle. Patients' self-assessment of the glycaemic profile (at fasting and 2 hr after the main meals) was performed weekly. Patients were constantly monitored for adverse events and episodes of hypoglycaemia, and all events were recorded. Decrease of mean fasting glucose levels measured in the first cycle was more pronounced in the group treated with G 5.0 mg/M 400 (p<0.01) compared to baseline, although the difference was not significant--no changes were observed in the second 3-month period. Results of patients' self-assessment of the glycaemic profile in the overall 6-month period show that the two trial drugs produced similar effects on fasting glucose, but the decrease of post-prandial glycaemic levels was markedly higher with G 5 mg/M 400 mg than with G 2.5 mg/M 400 mg at both main meals. A similar significant decrease (p<0.01) of HbA1c was observed in both sequence groups at the end of the first 3-month treatment period, and mean levels remained unchanged at 6 months. Drug-related adverse events were observed in 2 patients during treatment with G 2.5 mg/M 400 mg and in 5 with G 5 mg/M 400 mg, while 14 and 22 episodes of hypoglycaemia occurred with the two trial drugs, respectively (p=NS between treatments). Metformin-induced increases of lactate levels were similar in the two sequence groups. No differences between groups were found either in the number of up-titrated patients or in all the other laboratory parameters. In conclusion, the new combination containing 5-mg glibenclamide produced a greater improvement in post-prandial glycaemic control compared with the standard fixed doses, and resulted equally safe and well tolerated.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"350-7"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25105317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.","authors":"E Mannucci,&nbsp;F Tesi,&nbsp;G Bardini,&nbsp;A Ognibene,&nbsp;M G Petracca,&nbsp;S Ciani,&nbsp;A Pezzatini,&nbsp;M Brogi,&nbsp;I Dicembrini,&nbsp;F Cremasco,&nbsp;G Messeri,&nbsp;C M Rotella","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Metformin has been shown to increase glucagon-like peptide-1 (GLP-1) levels after an oral glucose load in obese non-diabetic subjects. In order to verify if this effect of the drug was also present in obese Type 2 diabetic patients who have never been treated with hypoglycemic drugs, 22 Type 2 diabetic and 12 matched non-diabetic obese patients were studied. GLP-1 was measured before and after a 100 g glucose load at baseline, after a single oral dose of 850 mg of metformin, and after 4 weeks of treatment with metformin 850 mg three times daily. Post-load GLP-1 levels were significantly lower in diabetic patients. A single dose of metformin did not modify GLP-1 levels. After 4 weeks of treatment, fasting GLP-1 increased in diabetic patients (3.8 vs 4.9 pmol/l; p<0.05), while the incremental area under the curve of GLP-1 significantly increased in both diabetic [93.6 (45.6-163.2) vs 151.2 (36.0-300.5) pmol x min/l; p<0.05] and non-diabetic [187.2 (149.4-571.8) vs 324.0 (238.2-744.0) pmol x min/l; p<0.05] subjects. In conclusion, GLP-1 levels after an oral glucose load in obese type 2 diabetic patients were increased by 4 weeks of metformin treatment in a similar fashion as in obese subjects with normal glucose tolerance.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"336-42"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25277280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of diabetes in pregnancy: a review of Italian data.","authors":"A Lapolla,&nbsp;M G Dalfrà,&nbsp;C Lencioni,&nbsp;G Di Cianni","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The prevalence of diabetes and impaired glucose tolerance in women of childbearing age is increasing worldwide, particularly among minority youth. As a consequence, in many parts of the world the number of pregnancies complicated by Type 2 diabetes is actually exceeding those complicated by Type 1 diabetes. Moreover, also the prevalence and incidence of gestational diabetes mellitus have been rising over recent years. Although diabetes complicating pregnancy is a cause of maternal and foetal complications, its exact prevalence in pregnancy is yet not well defined and large population studies are still lacking. This article reviews the existing epidemiologic studies on diabetes in pregnancy performed in Italy.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"358-67"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25105318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparision of interleukin-6 and malondialdehyde levels in diabetic patients in Taiwan.","authors":"Y R Wen,&nbsp;L P Chang,&nbsp;H L Chen,&nbsp;C F Liu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The purpose of this study was to compare the levels of interleukin-6 (IL-6) and malondialdehyde (MDA) in healthy controls and diabetic patients without coronary heart disease (CHD). Fasting serum IL-6 and MDA were determined in 30 healthy controls and 52 (20 Type 1 and 32 Type 2) diabetic patients without clinical evidence of CHD. MDA was calculated as oxidative stress. The IL-6 concentration was used to evaluate the cytokine function. Results showed that the serum IL-6 and MDA concentrations are significantly higher in Type 2 diabetic patients (p<0.05). In conclusion, we demonstrated that Type 2 diabetic patients are more influenced by oxidative stress than Type 1 diabetic patients and healthy controls, because of the action of cytokine.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"368-70"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25105319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italian Society of Diabetology Mentor Award. The stages of Type 1A diabetes: retrospective and prospective.","authors":"G S Eisenbarth","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In 1986, enough information was available based on studies by investigators from four continents to propose a model of the pathogenesis of Type 1A diabetes. The model divided pathogenesis into a series of stages with the proposal that insulin-dependent diabetes was a chronic autoimmune disorder. Long-term studies of non-diabetic identical twins of patients with Type 1A diabetes indicated that chronic loss of the ability to secrete insulin preceded the onset of diabetes in the presence of both genetic susceptibility and expression of anti-islet autoantibodies. It is now clear that the great majority of individuals who develop Type 1A diabetes show both immunologic and metabolic abnormalities before the development of overt diabetes. A combination of detection of anti-islet autoantibodies, genetic characteristics and metabolic abnormalities can now be used to predict Type 1A diabetes as well as approximate timing of diabetes onset. This knowledge has led to clinical trials on the prevention of Type 1A diabetes that hope to harness a remarkable increase in basic immunologic knowledge and a new generation of immunomodulatory therapies. Despite this increase in knowledge of the natural history of Type 1A diabetes and pathogenesis in animal models, much remains to be defined to allow efficient and successful disease prevention.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"374-85"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25105321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between levels of alpha1-acid glycoprotein and metabolic parameters of diabetes mellitus.","authors":"E Akbay,&nbsp;I Yetkin,&nbsp;R Ersoy,&nbsp;S Kulaksizoğlu,&nbsp;F Törüner,&nbsp;M Arslan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study was to investigate the relationship of alpha1-acid glycoprotein (AGP, orosomucoid), which is an acute-phase reactant, in patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM), with the metabolic parameters and complications of diabetes mellitus. A total of 119 diabetic patients (89 T2DM, 30 T1DM) and 33 healthy controls were included in the study. The mean AGP level in the diabetic group was not different from the control group (82.4 +/- 28.9 and 81.6 +/- 16.6 mg/dl, respectively), but it was higher in T2DM than in T1DM subjects (86.6 +/- 28.3 and 69.7 +/- 26.9, respectively). AGP plasma levels showed a significant correlation with age and body mass index (r = +0.348 and r = +0.296, respectively). AGP plasma levels resulted higher in obese diabetic patients (97.7 +/- 28.0) than in non-obese diabetic patients (77.6 +/- 28.7 mg/dl) and controls (81.6 +/- 16.6), and also higher in diabetic subjects with poor glycaemic control (85.1 +/- 33.3 mg/dl) than in diabetic subjects with optimal glycaemic control (79.5 +/- 23.1 mg/dl). A relationship between AGP and macro- and microvascular complications of diabetes mellitus was not found. In conclusion, inflammatory findings were more prominent in obese diabetic patients.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"331-5"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25277279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strain variability in Zucker rats affects their response to oral oleoyl-estrone.","authors":"M Díaz-Silva,&nbsp;M M Grasa,&nbsp;M Blay,&nbsp;J A Fernández-López,&nbsp;X Remesar,&nbsp;M Alemany","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>There is a considerable variability in the responses of Zucker fa/fa rats in metabolic studies, which could not be solely attributed to the leprfa mutation. In order to fathom the extent of this variability, we compared the response to oleoyl-estrone (OE), a powerful lipid-mobilising agent, of two strains of Zucker lean and obese rats: Harlan (H) and Charles River (CR). Rats were given an oral gavage of 10 micromol/day/kg of OE in sunflower oil, and were compared with oil-receiving controls. Body composition, energy and water balances, and plasma parameters were studied after 10 days of treatment. H rats showed a higher water turnover than CR rats; OE treatment reduced water intake, partly compensated by metabolic water, and decreased stool water. H rats accrued more cholesterol than CR animals, which showed higher cholesterolaemia. OE facilitated cholesterol disposal in lean (CR and H) and H obese rats. CR rats had higher body and liver lipids than H animals. No differences in energy balance were found. Insulin decrease following OE treatment was greater in lean CR than in H rats, but this trend was reversed in the obese rats, lacking effective responses to leptin. The red cell glucose compartment was smaller in H than in CR rats; the higher insulin levels in H rats may be partly responsible for that difference. Obese H maintained glycaemia (and liver glycogen) with higher insulin levels than CR animals. The extent to which the leprfa mutation affects the responses of Zucker fa/fa rats could not be singled out unless the metabolic environment of the batch used is known. This variability must be taken into account when developing a metabolic or hormonal study in which this model of obesity is used.</p>","PeriodicalId":79867,"journal":{"name":"Diabetes, nutrition & metabolism","volume":"17 6","pages":"315-22"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25277277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}